Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer

IMPORTANCE: Although the activity of pembrolizumab and lenvatinib (the only US Food and Drug Administration–approved immunotherapy for mismatch repair proficient endometrial cancer [MMRP EC]) is compelling, there are no biomarkers of response and most patients do not tolerate, do not respond to, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Konstantinopoulos, Panagiotis A., Gockley, Allison A., Xiong, Niya, Krasner, Carolyn, Horowitz, Neil, Campos, Susana, Wright, Alexi A., Liu, Joyce F., Shea, Meghan, Yeku, Oladapo, Castro, Cesar, Polak, Madeline, Lee, Elizabeth K., Sawyer, Hannah, Bowes, Brittany, Moroney, John, Cheng, Su-Chun, Tayob, Nabihah, Bouberhan, Sara, Spriggs, David, Penson, Richard T., Fleming, Gini F., Nucci, Marisa R., Matulonis, Ursula A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335244/
https://www.ncbi.nlm.nih.gov/pubmed/35900726
http://dx.doi.org/10.1001/jamaoncol.2022.2181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335244/
https://www.ncbi.nlm.nih.gov/pubmed/35900726
http://dx.doi.org/10.1001/jamaoncol.2022.2181

Ejemplares similares